Arm Holdings CEO Discusses AI's Potential in Cancer Research and Robotics Amid Chip Shortage

Rene Haas, chief executive of Arm Holdings, a Cambridge-based chip designer, stated that artificial intelligence (AI) will eventually find a cure for cancer that humans cannot achieve within their lifetimes. In an interview with the BBC, Haas noted that while current models of how DNA markers are affected by cancer are too complex for both humans and existing computers, advancements in AI will enable solutions in the future. He also mentioned that the rapid growth of AI technology is currently hindered by a shortage of chips necessary for building data centers. Haas expressed skepticism about the feasibility of manufacturing chips in the UK, despite government discussions on the topic. Arm Holdings designs microchips used in various devices worldwide, and Haas highlighted the company's significant market value during the recent AI boom. He emphasized that AI will lead to the development of humanoid robots in the next five years, capable of performing various tasks in sectors such as manufacturing and cleaning. Haas addressed concerns about job losses due to AI, suggesting that while some changes are expected, the overall impact will create new opportunities. He remarked on the high demand for Arm's microchips, particularly the Arm AGI chip, which has seen over $2 billion in demand since its launch in March. Haas also pointed out the ongoing challenges in chip supply, which he believes are impeding the expansion of AI and data centers. He mentioned ambitious plans for large data centers in France and the US, as well as potential projects in space, while stressing the need for more chip factories. Despite the centralization of chip manufacturing around companies like TSMC in Taiwan, Haas does not foresee the UK becoming a manufacturing hub due to the high costs and resources required. He defended Arm's position, noting that half of its workforce remains in the UK and it is the largest employer in Cambridge.